Amgen Q3 2026 slides: six growth drivers fuel 8% revenue gain
Amgen reported Q3 2026 revenue of $10.4B, up 8% YoY, and adjusted EPS of $6.45, up 14%. Six key growth drivers contributed 70% of product sales, with notable gains in cardiovascular, bone health, and rare disease products. The company raised full-year guidance and increased its dividend by 6%.
How this was made
The 30-second read
Why it matters
Guidance raise to $38.9‑$39.7B revenue and $22.90‑$23.70 EPS may lift the stock despite a modest after‑hours dip.
Market read
Large‑cap biotech earnings with guidance uplift, likely influencing sector sentiment and investor positioning.
What to watch
Higher R&D spend may pressure cash flow later; investors should watch upcoming pipeline milestones.
Background
Amgen's Q3 2026 earnings release provides updated financial metrics and guidance for the year.
Ticker impact
Amgen reported Q3 2026 earnings with 8% revenue growth, beat expectations, and raised full-year guidance.
potential upside as investors price in higher revenue and EPS guidance
Strong top‑line growth, margin stability, and raised guidance outweigh the small after‑hours dip.
Market effects
Biotech sector may see broader optimism from Amgen's strong performance and guidance raise.
U.S. large‑cap biotech stocks could see modest buying pressure.
Amgen's results may influence global pharma investors tracking growth drivers.
Counterpoint
The after‑hours price decline suggests market skepticism; a pullback could present a short‑term entry.
Key entities
- ExecutiveRobert A. Bradway
Chairman and CEO of Amgen who commented on the results.
